课题基金 / 基金详情

项目摘要

项目成果

Harry Alan Quigley的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The loss of vision caused by glaucoma results from death of retinal ganglion cells (RGC), whose intraretinal environment consists of interacting processes, some of which promote survival and others that lead toward death. This project studies initial alterations in the balance between life and death of RGC in both experimental models of glaucoma in mice and in the post-mortem ocular tissue of persons with glaucoma. It has identified and will clarify the first steps in RGC death, and will investigate interventions that prevent RGC loss in the second leading cause of worldwide blindness. First, we determine the role of specific connective tissue elements in the sclera that transmit intraocular pressure (IOP)-induced force directly and indirectly into RGC injury. A series of carefully chosen transgenic mouse strains will be studied to identify what alterations in the biomechanical response of the eye to IOP are most likely to either increase or decrease neuronal injury as measured in acute and chronic mouse glaucoma models. Since half of those with open-angle glaucoma suffer RGC loss at normal IOP levels, we will determine candidate molecules and interactions in the eye¿s support tissues that encourage glaucoma damage at normal IOP. Second, we will determine the extent to which altered capillary function at the optic nerve head contributes to RGC damage, perhaps mediated by tumor necrosis factor alpha and endothelin. Failure of normal vascular nutrition is generally agreed to play a role in glaucoma, but the mechanism(s) of actual damage have not been detailed. Finally, we will dissect how cjun n-terminal kinase participates as an initial signal to start RGC death. Transgenic mice deficient in this molecule will be used to determine the potential therapeutic benefit of eliminating this signal. The project will synthesize some areas of present knowledge about early glaucoma injury to derive a cohesive picture for potential new therapy. Candidate molecules for genetic susceptibility to glaucoma are likely to be identified.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
A clinicopathologic study of optic neuropathies associated with intracranial mass lesions with quantification of remaining axons.
与颅内肿块病变相关的视神经病变的临床病理学研究以及剩余轴突的量化。
DOI: 10.1016/s0002-9394(14)78297-2
发表时间: 1983
期刊: American journal of ophthalmology
影响因子: 4.2
作者: [Levin,PS, Newman,SA, Quigley,HA, Miller,NR]
通讯作者: Miller,NR
Specular microscopy of irido-corneal endothelial syndrome.
虹膜角膜内皮综合征的镜面显微镜。
DOI: 10.1111/j.1442-9071.1980.tb01672.x
发表时间: 1980
期刊: Australian journal of ophthalmology
影响因子: --
作者: [Hirst,LW, Quigley,HA, Stark,WJ, Shields,NB]
通讯作者: Shields,NB
DOI: 10.1016/0039-6257(85)90080-3
发表时间: 1985
期刊: Survey of ophthalmology
影响因子: 5.1
作者: [Quigley,HA]
通讯作者: Quigley,HA
DOI: --
发表时间: 1984-08
期刊: Investigative ophthalmology & visual science
影响因子: 4.4
作者: [H. Quigley;R. Hohman;E. M. Addicks;W. Green]
通讯作者: H. Quigley;R. Hohman;E. M. Addicks;W. Green
18
    CORE--TRANSMISSION & IMAGING EM
    • 批准号:
      6993157
    • 项目类别:
    • 资助金额:
      $12.32万
    • 财政年份:
      2004
    • 负责人:
      Harry Alan Quigley
    • 依托单位:
    The Wilmer Institute Mentored Clinician Scientist Scholar Program-Supplement
    • 批准号:
      10405937
    • 项目类别:
    • 资助金额:
      $8.64万
    • 财政年份:
      2003
    • 负责人:
      Harry Alan Quigley
    • 依托单位:
    The Wilmer Institute Mentored Clinical-Scientist Scholar Program
    • 批准号:
      8088099
    • 项目类别:
    • 资助金额:
      $35.31万
    • 财政年份:
      2003
    • 负责人:
      Harry Alan Quigley
    • 依托单位:
    The Wilmer Institute Mentored Clinical-Scientist Scholar Program
    • 批准号:
      8509693
    • 项目类别:
    • 资助金额:
      $48.69万
    • 财政年份:
      2003
    • 负责人:
      Harry Alan Quigley
    • 依托单位:
    海外基金